Cargando…
Comparative effectiveness of generic nifedipine versus Adalat long‐acting nifedipine for hypertension treatment: A multi‐institutional cohort study
This retrospective multi‐institutional database analysis aimed to evaluate the blood‐pressure‐lowering efficacy and clinical outcomes of a generic versus brand‐name nifedipine for hypertension management. A total of 12 693 patients who were prescribed a generic or brand‐name nifedipine between Janua...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106077/ https://www.ncbi.nlm.nih.gov/pubmed/35384251 http://dx.doi.org/10.1111/jch.14478 |
_version_ | 1784708195937157120 |
---|---|
author | Tung, Ying‐Chang Lin, Chia‐Pin Hsiao, Fu‐Chih Ho, Chien‐Te Tzyy‐Jer, Hsu Chu, You‐Chia Chen, Wen‐Jone Chu, Pao‐Hsien |
author_facet | Tung, Ying‐Chang Lin, Chia‐Pin Hsiao, Fu‐Chih Ho, Chien‐Te Tzyy‐Jer, Hsu Chu, You‐Chia Chen, Wen‐Jone Chu, Pao‐Hsien |
author_sort | Tung, Ying‐Chang |
collection | PubMed |
description | This retrospective multi‐institutional database analysis aimed to evaluate the blood‐pressure‐lowering efficacy and clinical outcomes of a generic versus brand‐name nifedipine for hypertension management. A total of 12 693 patients who were prescribed a generic or brand‐name nifedipine between January 1, 2011, and December 31, 2018, were identified from the Chang Gung Research Database of Chang Gung Memorial Hospitals, Taiwan. Among them, 2112 (21.4%) were prescribed generic nifedipine. After propensity score matching, both the generic and brand‐name groups consisted of 2102 patients. At a mean follow‐up of 3 years, the changes in office systolic (p for interaction = .791) and diastolic blood pressure (p for interaction = .689) did not differ significantly between the patients who received the generic and the brand‐name nifedipine. There was no significant difference between the two study groups regarding the composite of all‐cause mortality, acute myocardial infarction, stroke, coronary revascularization, or hospitalization for heart failure (hazard ratio 0.98, 95% confidence interval 0.85–1.13; p = .774). In conclusion, the generic nifedipine was comparable to its brand‐name counterpart regarding office blood pressure reduction and the composite cardiovascular outcome for the treatment of patients with hypertension. |
format | Online Article Text |
id | pubmed-9106077 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91060772022-05-18 Comparative effectiveness of generic nifedipine versus Adalat long‐acting nifedipine for hypertension treatment: A multi‐institutional cohort study Tung, Ying‐Chang Lin, Chia‐Pin Hsiao, Fu‐Chih Ho, Chien‐Te Tzyy‐Jer, Hsu Chu, You‐Chia Chen, Wen‐Jone Chu, Pao‐Hsien J Clin Hypertens (Greenwich) Treatment This retrospective multi‐institutional database analysis aimed to evaluate the blood‐pressure‐lowering efficacy and clinical outcomes of a generic versus brand‐name nifedipine for hypertension management. A total of 12 693 patients who were prescribed a generic or brand‐name nifedipine between January 1, 2011, and December 31, 2018, were identified from the Chang Gung Research Database of Chang Gung Memorial Hospitals, Taiwan. Among them, 2112 (21.4%) were prescribed generic nifedipine. After propensity score matching, both the generic and brand‐name groups consisted of 2102 patients. At a mean follow‐up of 3 years, the changes in office systolic (p for interaction = .791) and diastolic blood pressure (p for interaction = .689) did not differ significantly between the patients who received the generic and the brand‐name nifedipine. There was no significant difference between the two study groups regarding the composite of all‐cause mortality, acute myocardial infarction, stroke, coronary revascularization, or hospitalization for heart failure (hazard ratio 0.98, 95% confidence interval 0.85–1.13; p = .774). In conclusion, the generic nifedipine was comparable to its brand‐name counterpart regarding office blood pressure reduction and the composite cardiovascular outcome for the treatment of patients with hypertension. John Wiley and Sons Inc. 2022-04-06 /pmc/articles/PMC9106077/ /pubmed/35384251 http://dx.doi.org/10.1111/jch.14478 Text en © 2022 The Authors. The Journal of Clinical Hypertension published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Treatment Tung, Ying‐Chang Lin, Chia‐Pin Hsiao, Fu‐Chih Ho, Chien‐Te Tzyy‐Jer, Hsu Chu, You‐Chia Chen, Wen‐Jone Chu, Pao‐Hsien Comparative effectiveness of generic nifedipine versus Adalat long‐acting nifedipine for hypertension treatment: A multi‐institutional cohort study |
title | Comparative effectiveness of generic nifedipine versus Adalat long‐acting nifedipine for hypertension treatment: A multi‐institutional cohort study |
title_full | Comparative effectiveness of generic nifedipine versus Adalat long‐acting nifedipine for hypertension treatment: A multi‐institutional cohort study |
title_fullStr | Comparative effectiveness of generic nifedipine versus Adalat long‐acting nifedipine for hypertension treatment: A multi‐institutional cohort study |
title_full_unstemmed | Comparative effectiveness of generic nifedipine versus Adalat long‐acting nifedipine for hypertension treatment: A multi‐institutional cohort study |
title_short | Comparative effectiveness of generic nifedipine versus Adalat long‐acting nifedipine for hypertension treatment: A multi‐institutional cohort study |
title_sort | comparative effectiveness of generic nifedipine versus adalat long‐acting nifedipine for hypertension treatment: a multi‐institutional cohort study |
topic | Treatment |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9106077/ https://www.ncbi.nlm.nih.gov/pubmed/35384251 http://dx.doi.org/10.1111/jch.14478 |
work_keys_str_mv | AT tungyingchang comparativeeffectivenessofgenericnifedipineversusadalatlongactingnifedipineforhypertensiontreatmentamultiinstitutionalcohortstudy AT linchiapin comparativeeffectivenessofgenericnifedipineversusadalatlongactingnifedipineforhypertensiontreatmentamultiinstitutionalcohortstudy AT hsiaofuchih comparativeeffectivenessofgenericnifedipineversusadalatlongactingnifedipineforhypertensiontreatmentamultiinstitutionalcohortstudy AT hochiente comparativeeffectivenessofgenericnifedipineversusadalatlongactingnifedipineforhypertensiontreatmentamultiinstitutionalcohortstudy AT tzyyjerhsu comparativeeffectivenessofgenericnifedipineversusadalatlongactingnifedipineforhypertensiontreatmentamultiinstitutionalcohortstudy AT chuyouchia comparativeeffectivenessofgenericnifedipineversusadalatlongactingnifedipineforhypertensiontreatmentamultiinstitutionalcohortstudy AT chenwenjone comparativeeffectivenessofgenericnifedipineversusadalatlongactingnifedipineforhypertensiontreatmentamultiinstitutionalcohortstudy AT chupaohsien comparativeeffectivenessofgenericnifedipineversusadalatlongactingnifedipineforhypertensiontreatmentamultiinstitutionalcohortstudy |